Quel est le prix pour Acrivon Therapeutics, Inc. Common Stock (ACRV)

Le prix pour Acrivon Therapeutics, Inc. Common Stock (ACRV) est $2.23

Quelle est la capitalisation boursière pour Acrivon Therapeutics, Inc. Common Stock (ACRV)

La capitalisation boursière pour Acrivon Therapeutics, Inc. Common Stock (ACRV) est $95.23M

Acrivon Therapeutics, Inc. Common Stock (ACRV) Divisions d'Actions

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.